Selective TYK2 Inhibitor Scaffold for Potency Without JAK Off-Targets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing JAK inhibitors lack selectivity for TYK2 over other JAK family members, leading to undesirable side effects and a narrow therapeutic index in treating autoimmune and inflammatory diseases.
Innovation Solution
Development of compounds that selectively inhibit TYK2 by forming a bicyclic heteroaryl ring system with specific substituents, providing high potency and selectivity for TYK2 over JAK1, JAK2, and JAK3.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule JAK inhibitors are developed to treat autoimmune diseases, then therapeutic efficacy is improved, but selectivity for specific JAK family members deteriorates leading to side effects
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that interact with unique structural characteristics of TYK2's ATP binding site. The compounds contain specific substituent patterns on the bicyclic heteroaryl ring system that form selective interactions with TYK2 amino acid residues, creating localized binding preferences that distinguish TYK2 from other JAK family members while maintaining potent inhibition.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds, including substituent types, positions, and configurations on the bicyclic heteroaryl core. By optimizing these parameters, the invention achieves a balance between binding affinity for TYK2 and selectivity against other JAKs, transforming the general JAK inhibition profile into a targeted TYK2-specific profile that reduces off-target effects.
2Adaptability or versatility
If pan-JAK inhibitors are used to treat autoimmune diseases, then broad therapeutic coverage is achieved, but selectivity for individual JAK family members is lost
Solution Approach 1:
The patent applies the inversion principle by reversing the conventional approach: instead of designing inhibitors that bind to conserved regions of the JAK family (which would provide broad coverage but low selectivity), the invention targets unique structural features of TYK2. This inverted strategy prioritizes selectivity through recognition of TYK2-specific structural elements, thereby achieving both precision and therapeutic effectiveness.
3Power
If JAK inhibitors are designed for high potency, then inhibition strength is improved, but selectivity across the kinome deteriorates
Solution Approach 1:
The patent applies the intermediary principle by introducing specific molecular mediators within the inhibitor structure that facilitate selective recognition. The bicyclic heteroaryl ring system acts as an intermediary scaffold that mediates selective interactions with TYK2 through specific substituent groups, enabling the molecule to achieve high binding affinity while maintaining discrimination against other kinases through carefully designed intermediate interaction points.
Data Source
AI summary
This disclosure relates to compounds of Formula (I), or pharmaceutically acceptable salt thereof: Formula (I) in which all of the variables are as defined in the application. The compounds of the present disclosure are capable of inhibiting the activity of tyrosine kinase 2 (TYK2). The disclosure further provides methods of preparing the compounds of the disclosure, and methods for their therapeutic use.